tradingkey.logo


tradingkey.logo


Veracyte Inc

VCYT
30.010USD
-2.790-8.51%
āļ›āļīāļ” 03/27, 16:00ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
620.90MāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
35.54P/E TTM


āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Veracyte Inc āļšāļĢāļīāļĐāļąāļ—

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.

āļ‚āđ‰āļ­āļĄāļđāļĨ Veracyte Inc


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™VCYT
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Veracyte Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļOct 30, 2013
āļ‹āļĩāļ­āļĩāđ‚āļ­Stapley (Marc A)
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™824
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Oct 30
āļ—āļĩāđˆāļ­āļĒāļđāđˆ6000 Shoreline Court, Suite 300
āđ€āļĄāļ·āļ­āļ‡SOUTH SAN FRANCISCO
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ OMX - NASDAQ BASIC
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ94080
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ16502436300
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://www.veracyte.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™VCYT
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļOct 30, 2013
āļ‹āļĩāļ­āļĩāđ‚āļ­Stapley (Marc A)

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ Veracyte Inc


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
215.70K
+12.57%
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Chief Financial Officer
Chief Financial Officer
75.35K
+31.54%
Ms. Annie Mcguire
Ms. Annie Mcguire
Chief Human Resources Officer, General Counsel
Chief Human Resources Officer, General Counsel
66.34K
+68.81%
Dr. Phillip G. (Phil) Febbo, M.D.
Dr. Phillip G. (Phil) Febbo, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
62.88K
+26.59%
Mr. John Leite, Ph.D.
Mr. John Leite, Ph.D.
Global Chief Commercial Officer
Global Chief Commercial Officer
58.61K
+51.15%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
50.97K
-22.51%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
32.81K
+28.41%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
27.84K
+17.00%
Mr. Evan Jones
Mr. Evan Jones
Independent Director
Independent Director
17.89K
-79.95%
Mr. Jens Holstein
Mr. Jens Holstein
Independent Director
Independent Director
15.73K
-63.59%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
215.70K
+12.57%
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Chief Financial Officer
Chief Financial Officer
75.35K
+31.54%
Ms. Annie Mcguire
Ms. Annie Mcguire
Chief Human Resources Officer, General Counsel
Chief Human Resources Officer, General Counsel
66.34K
+68.81%
Dr. Phillip G. (Phil) Febbo, M.D.
Dr. Phillip G. (Phil) Febbo, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
62.88K
+26.59%
Mr. John Leite, Ph.D.
Mr. John Leite, Ph.D.
Global Chief Commercial Officer
Global Chief Commercial Officer
58.61K
+51.15%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
50.97K
-22.51%

āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰

āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 6 āļĄ.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 6 āļĄ.āļ„.
FY2024
FY2023
FY2022
FY2021
FY2020
āļ‚āđ‰āļ­āļĄāļđāļĨāļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡āļĒāļąāļ‡āđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāđ€āļ›āļīāļ”āđ€āļœāļĒāļˆāļēāļāļ—āļēāļ‡āļšāļĢāļīāļĐāļąāļ—
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
United States
423.54M
95.01%
International
22.23M
4.99%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āļ‚āđ‰āļ­āļĄāļđāļĨāļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡āļĒāļąāļ‡āđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāđ€āļ›āļīāļ”āđ€āļœāļĒāļˆāļēāļāļ—āļēāļ‡āļšāļĢāļīāļĐāļąāļ—

āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™

āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļĪāļŦāļąāļŠāļ—āļĩāđˆ 19 āļ.āļž.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļĪāļŦāļąāļŠāļ—āļĩāđˆ 19 āļ.āļž.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
BlackRock Institutional Trust Company, N.A.
14.49%
The Vanguard Group, Inc.
10.68%
Artisan Partners Limited Partnership
7.88%
Fidelity Management & Research Company LLC
6.14%
State Street Investment Management (US)
5.49%
āļ­āļ·āđˆāļ™ āđ†
55.32%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
BlackRock Institutional Trust Company, N.A.
14.49%
The Vanguard Group, Inc.
10.68%
Artisan Partners Limited Partnership
7.88%
Fidelity Management & Research Company LLC
6.14%
State Street Investment Management (US)
5.49%
āļ­āļ·āđˆāļ™ āđ†
55.32%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Investment Advisor
65.05%
Investment Advisor/Hedge Fund
34.56%
Hedge Fund
5.48%
Research Firm
3.32%
Pension Fund
1.80%
Individual Investor
0.91%
Bank and Trust
0.60%
Holding Company
0.17%
Family Office
0.03%

āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļĪāļŦāļąāļŠāļ—āļĩāđˆ 1 āļĄ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļĪāļŦāļąāļŠāļ—āļĩāđˆ 1 āļĄ.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q4
654
89.69M
113.46%
-3.72M
2025Q3
616
87.37M
110.53%
-1.45M
2025Q2
598
84.22M
107.53%
-1.90M
2025Q1
612
85.86M
109.67%
-679.43K
2024Q4
593
81.64M
104.75%
-2.62M
2024Q3
567
81.88M
106.62%
-2.30M
2024Q2
533
81.65M
106.83%
-3.86M
2024Q1
532
81.30M
103.75%
+1.22M
2023Q4
524
76.49M
104.40%
-3.87M
2023Q3
520
77.05M
105.90%
-3.78M
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™


āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
BlackRock Institutional Trust Company, N.A.
11.32M
14.32%
+5.19M
+84.79%
Sep 30, 2025
The Vanguard Group, Inc.
8.49M
10.74%
+403.74K
+5.00%
Sep 30, 2025
Artisan Partners Limited Partnership
7.37M
9.32%
+1.05M
+16.59%
Sep 30, 2025
Fidelity Management & Research Company LLC
5.75M
7.27%
-1.18M
-17.05%
Sep 30, 2025
State Street Investment Management (US)
4.20M
5.31%
+1.03M
+32.49%
Sep 30, 2025
ARK Investment Management LLC
4.47M
5.65%
+665.69K
+17.52%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
3.12M
3.94%
+95.66K
+3.17%
Sep 30, 2025
Wellington Management Company, LLP
3.37M
4.27%
-100.55K
-2.89%
Sep 30, 2025
Geode Capital Management, L.L.C.
1.89M
2.39%
-39.95K
-2.07%
Sep 30, 2025
ArrowMark Colorado Holdings, LLC
2.55M
3.22%
-33.08K
-1.28%
Sep 30, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Invesco Biotechnology & Genome ETF
4.35%
ARK Genomic Revolution ETF
3.68%
First Trust NYSE Arca Biotechnology Index Fund
3.48%
Global X Genomics & Biotechnology ETF
3.13%
ROBO Global Healthcare Technology & Innovation ETF
2.19%
Invesco S&P SmallCap 600 Pure Growth ETF
1.97%
Invesco S&P SmallCap Health Care ETF
1.74%
Franklin Genomic Advancements ETF
1.45%
ROBO Global Artificial Intelligence ETF
1.43%
ARK Innovation ETF
1.24%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
Invesco Biotechnology & Genome ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™4.35%
ARK Genomic Revolution ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.68%
First Trust NYSE Arca Biotechnology Index Fund
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.48%
Global X Genomics & Biotechnology ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.13%
ROBO Global Healthcare Technology & Innovation ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.19%
Invesco S&P SmallCap 600 Pure Growth ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.97%
Invesco S&P SmallCap Health Care ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.74%
Franklin Genomic Advancements ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.45%
ROBO Global Artificial Intelligence ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.43%
ARK Innovation ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.24%

āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ


āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 0.00 USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™


āļ§āļąāļ™āļ—āļĩāđˆ
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
KeyAI
î™